Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13129	CFI-400945 free base
BP13129	CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
BP13130	CGP60474
BP13130	CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently.
BP13131	Chebulinic acid
BP13131	Chebulinic acid is a potent inhibitor of M. tuberculosis DNA gyrase. It also can inhibit SMAD-3 phosphorylation and H+ K+-ATPase activity.
BP13132	CHK1 inhibitor
BP13132	CHK1 inhibitor (GDC-0575 analog) is a CHK1 inhibitor.
BP13133	SCH900776
BP13133	CHK1 Inhibitor MK-8776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
BP13134	CHK1-IN-3
BP13134	CHK1-IN-2 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 0.4 nM).
BP13135	CHK1-IN-2
BP13135	CHK1-IN-2 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 6 nM).
BP13136	CHK1-IN-4
BP13136	CHK1-IN-4 is a potent inhibitor of checkpoint kinase 1 (chk1) and potently inhibits chk1 phosphorylation in the tumor cells with anti-tumor activity.
BP13137	CHK-IN-1
BP13137	CHK-IN-1 is a CHK1 and CHK2 inhibitor, has anti-proliferative activities.
BP13138	CID 5951923
BP13138	CID 5951923 is an inhibitor of KLF5 transcription factor with an IC50 of 603 nM.
BP13139	CID 2011756
BP13139	CID-2011756 is an ATP-competitive and specific PKD1 inhibitor.
BP13140	CID44216842
BP13140	CID44216842 is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe.
BP13141	Cidofovir
BP13141	Cidofovir inhibits virus replication by specific inhibition of viral DNA synthesis.
BP13142	CK7
BP13142	CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
BP13143	CKI-7
BP13143	CKI-7 2HCl is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 2HCl also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
BP13144	Clausine Z
BP13144	Clausine Z exhibits inhibitory activity against cyclin-dependent kinase 5 (CDK5) and shows protective effects on cerebellar granule neurons in vitro.
BP13145	Clevudine
BP13145	Clevudine is a synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA), therefore the patient is less likely to have a relapse after treatment is discontinued.
BP13146	CLK1-IN-1
BP13146	CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).
BP13147	CLK-IN-T3
BP13147	CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.
BP13148	CMPD101
BP13148	CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM, 2.3 μM, 1.4 μM and 8.1 μM, respectively.